Chris Lange

Chris Lange is an analyst for 24/7 Wall St., based in Houston. He has covered financial markets over the past five years with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and has helped start a small business.

Lastest Stories by Chris Lange

Although investors were disappointed with the Micron Technology quarterly results, analysts looked further out and were fairly positive.
The name of the game for restaurants during the government-mandated COVID-19 lockdowns has been delivery, and nobody does that better than pizza companies.
The parent of Array Technologies has amended its filing with the SEC regarding its initial public offering.
Moderna and Regeneron Pharmaceuticals each announced positive news late on Tuesday about their respective COVID-19 vaccine trials.
Beyond Meat shares hit a multiyear high on Tuesday after the company announced that it would expand its long-standing relationship with Walmart.
Aptorum shares absolutely exploded on Tuesday after the company announced that it would be launching a subsidiary focused on novel technologies targeting infectious diseases.
Security software company McAfee has filed with SEC regarding its initial public offering
McCormick reported better than expected second-quarter financial results and a 2-for-1 stock split before the markets opened on Tuesday.
Genfit SA (NASDAQ: GNFT) shot up on Monday after the company announced an agreement with Lab Corporation of America Holdings (NYSE: LH). This agreement is ultimately for Genfit’s technology to...
Eiger BioPharmaceuticals has announced disappointing results from a study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.
Piedmont Lithium has announced a binding agreement with Tesla to supply spodumene concentrate from its North Carolina deposit. Shares of Piedmont nearly tripled on the news.
Aquestive Therapeutics said that it had received a negative response from the FDA concerning its treatment for the management of seizure clusters.
Things aren’t looking up for Inovio Pharmaceuticals, after the FDA notified the company that it was placing a partial hold on its COVID-19 vaccine study.
24/7 Wall St. has previewed PepsiCo, Micron Technology and some of the other key companies expected to report results this week.
As more states loosen gambling restrictions, Argus expects DraftKings to benefit from its market leadership.